Eli Lilly Stock Drops 2.95% in Third Consecutive Day of Losses, Trading Volume Ranks 19th

On May 21, 2025, Eli Lilly (LLY) experienced a significant decline, with its stock price dropping by 2.95%, marking the third consecutive day of losses. Over the past three days, the company's stock has decreased by a total of 4.28%. The trading volume for the day was substantial, with a total of 29.29 billion shares exchanged, placing Eli Lilly at the 19th position in terms of trading volume for the day.

Cigna has announced a new deal that will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound. This move is part of an add-on to its pharmacy benefit and aims to make these medications more accessible to patients. The deal includes a simplified pre-authorization process and ensures that patients can access the drugs at the same price across retail pharmacies or through Evernorth's home delivery service.

Eli Lilly's Zepbound, along with Novo Nordisk's Wegovy, has shown promising results in clinical trials, demonstrating their effectiveness in weight loss. This new deal by Cigna is expected to bring down the costs for employers and their workers, making the drugs more affordable. For those who have been hesitant to cover the medications due to cost, capping employee out-of-pocket costs at $200 would amount to less than half the price consumers pay in cash without insurance.

Eli Lilly has also been working with healthcare providers, government entities, and industry partners to find creative solutions that help people with obesity access Zepbound. The company's efforts to make these weight-loss drugs more accessible are part of a broader strategy to regain its competitive edge in the weight loss drug market.